TG Therapeutics, Inc. (NASDAQ:TGTX) increased its full-year 2026 revenue guidance after reporting another quarter of strong sales growth for its multiple sclerosis treatment, Briumvi, according to the company’s latest earnings release.
The company generated total global revenue of $240.3 million during the second quarter, compared with $141.1 million in the same period last year.
Briumvi Continues to Drive Revenue Growth
U.S. net product revenue from Briumvi reached $227.7 million for the quarter ended June 30, 2026, representing a 64% increase from the second quarter of 2025.
For the first half of the year, Briumvi generated U.S. net product revenue of $422.5 million, up from $258.5 million recorded during the first six months of 2025.
The continued commercial momentum prompted TG Therapeutics to increase its full-year financial expectations.
The company now expects total global revenue of approximately $950 million in 2026 and forecasts U.S. Briumvi net product revenue in the range of $890 million to $905 million.
Higher Investment Weighs on Quarterly Profit
Net income for the second quarter totaled $7.8 million, compared with $28.2 million in the same quarter last year.
The decline reflected a significant increase in operating expenses, which rose to $218.7 million from $106.3 million a year earlier.
Research and development spending climbed to $95.3 million from $31.8 million, driven in part by $54.6 million related to subcutaneous manufacturing and secondary manufacturing activities.
Selling, general and administrative expenses also increased, rising to $82.1 million from $55.6 million in the prior-year period.
Cash Position Strengthens
Despite the higher level of investment, TG Therapeutics ended the quarter with a substantially stronger balance sheet.
Cash, cash equivalents and investment securities totaled $612.3 million as of June 30, 2026, compared with $199.5 million at the end of 2025.
Clinical Pipeline Continues to Advance
Alongside its commercial progress, TG Therapeutics also reported positive topline findings from the Phase 3 ENHANCE study.
The trial showed that a single 600 mg infusion of Briumvi administered on Day 1 achieved bioequivalent drug exposure to the currently approved two-dose induction regimen.
The company expects topline results from its Phase 3 study evaluating the subcutaneous formulation of Briumvi by the end of 2026 or early 2027.
TG Therapeutics also announced the launch of Phase 2 clinical trials investigating Briumvi as a potential treatment for myasthenia gravis and treatment-resistant schizophrenia.